Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,107 shares of the biotechnology company’s stock, valued at approximately $127,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Headlands Technologies LLC purchased a new position in Cerevel Therapeutics in the first quarter worth $26,000. Pacific Capital Wealth Advisors Inc. bought a new stake in shares of Cerevel Therapeutics during the 4th quarter valued at $71,000. Centaurus Financial Inc. bought a new stake in shares of Cerevel Therapeutics during the 4th quarter valued at $119,000. Virtu Financial LLC bought a new position in Cerevel Therapeutics in the 4th quarter worth about $246,000. Finally, Aigen Investment Management LP bought a new position in Cerevel Therapeutics in the 4th quarter worth about $348,000. Institutional investors own 87.73% of the company’s stock.
Insider Buying and Selling
In other Cerevel Therapeutics news, Director N Anthony Coles sold 25,000 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $41.18, for a total value of $1,029,500.00. Following the sale, the director now directly owns 25,928 shares of the company’s stock, valued at $1,067,715.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.10% of the stock is owned by insiders.
Cerevel Therapeutics Stock Performance
Cerevel Therapeutics (NASDAQ:CERE – Get Free Report) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.12). On average, equities research analysts anticipate that Cerevel Therapeutics Holdings, Inc. will post -2.59 EPS for the current year.
About Cerevel Therapeutics
Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.
Recommended Stories
- Five stocks we like better than Cerevel Therapeutics
- What is a Special Dividend?
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- How to Invest in the Best Canadian StocksĀ
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Cerevel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerevel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.